Sunflower Pharmaceutical Group (002737.SZ): Distribute 10 times 1.5 yuan for equity in 2023, with a registration date of June 13.
On ****, Gelonhui reported that Sunflower Pharmaceutical Group (002737.SZ) announced its annual equity distribution plan for 2023: based on the total existing share capital of 584,000,000 shares after deducting 0 shares of repurchased stocks, cash dividends of RMB 15.000000 per 10 shares will be distributed to all shareholders. The registration date for this equity distribution is June 13, 2024, and the ex-dividend date is June 14, 2024.
Costs rose, inventories were high, and Sunflower Pharmaceutical's first-quarter performance both declined to “return to the original form”
Beginning in the fourth quarter of last year, the decline in both revenue and profit has already begun.
China Grants Marketing Authorization to Sunflower Pharma's Electrolyte Powder for Constipation
China's medical products administrator granted marketing authorization to Sunflower Pharmaceutical (SHE:002737) subsidiary Harbin Sunflower Pharmaceutical's compound polyethylene glycol electrolyte po
Express News | Sunflower Pharmaceutical: Compound polyethylene glycol electrolyte dispersion was approved for marketing
Sunflower Pharmaceutical (002737) 2023 Annual Report and 2024 Quarterly Report Review Report: Solid Management and Active Layout of the “Sixth Five-Year Plan”
Incident: Sunflower Pharmaceutical issued an announcement on April 26, 2024: In 2023, the company achieved operating income of 5.70 billion yuan, an increase of 11.89% over the previous year; net profit to mother was 1,119 billion yuan, an increase of 29 billion yuan over the previous year.
Sunflower Pharmaceutical: The upward pressure on future costs may ease
Sunflower Pharmaceutical recently stated in a conference call with institutional investors that in terms of gross margin, from the beginning of the fourth quarter of last year to the first quarter of this year, the increase in prices of raw materials for Chinese herbal medicines has put some upward pressure on raw material costs. Looking at it now, after the price of Chinese herbal medicines has reached a high level, with the exception of individual varieties, it is generally in a steady state of decline, and the upward pressure on costs may ease in the future. In the past year, the company's gold single product strategy was effectively implemented. The annual shipment amount of liver protection tablets exceeded 1 billion yuan for the first time, making it the first 1 billion single product in the company's history. The basic market for children's respiratory products is stable, and the product matrix continues to be stable
Cinda Securities released a research report on April 27 stating that it gave Sunflower Pharmaceutical (002737.SZ) an increase in holdings rating. The main reasons for the rating include: 1) completing the “Fifth Five-Year Plan” with excellent performance,
Cinda Securities released a research report on April 27 stating that it gave Sunflower Pharmaceutical (002737.SZ) an increase in holdings rating. The main reasons for the rating include: 1) completing the “Fifth Five-Year Plan” with excellent performance, with a proposed dividend ratio of about 78% in 2023; 2) the “buy, reform, cooperation, research and generation” strategy to create the company's second driving force for growth; 3) 2024Q1's high base put pressure on 2024Q1 performance, and the “Sixth Five-Year Plan” began a new journey. (Mainichi Keizai Shimbun)
Sunflower Pharmaceutical (002737): Record performance in 2023, the “Sixth Five-Year Plan” points to a sales scale of 10 billion
Incident: The company released its 2023 annual report and 2024 quarterly report. In 2023, it achieved operating income of 5.7 billion yuan (yoy +12%) and net profit of 1,119 billion yuan (yoy +29%).
Sunflower Pharmaceutical (002737): The “Six Five-Year Plan” proposes 10 billion sales targets, high dividends, high-quality assets
Event: On April 25, 2024, the company released the 2023 Annual Report and the First Quarter 2024 Report. In 2023, the company achieved revenue of 5.70 billion yuan, an increase of 11.89% over the previous year, in fact
Sunflower Pharmaceutical (002737.SZ)'s net profit for 2023 increased by 29.05% to 1,119 billion yuan, and plans to pay 10 to 15 yuan
Gelonghui, April 25 | Sunflower Pharmaceutical (002737.SZ) released its 2023 annual report. As of the end of 2023, the company's total assets were 6.882 billion yuan and net assets to the mother were 4.763 billion yuan; in 2023, the company's operating income was 5.70 billion yuan, up 11.89% from 2022; and achieved net profit of 1,119 billion yuan, an increase of 29.05% over 2022. It is proposed to distribute a cash dividend of 15 yuan (tax included) for every 10 shares to all shareholders. The company wins with strategy first and model, shifting from “marketing-driven” to “marketing-driven and product-driven”, using culture and talent
Sunflower Pharmaceutical (002737.SZ)'s net profit for the first quarter of 255 million yuan decreased 37.17% year over year
On April 25, Ge Longhui Pharmaceutical (002737.SZ) released its report for the first quarter of 2024. Operating income during the reporting period was 1,518 billion yuan, a year-on-year decrease of 14.01%; net profit attributable to shareholders of listed companies was 255 million yuan, a year-on-year decrease of 37.17%; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 237 million yuan, a year-on-year decrease of 39.18%; and basic earnings per share were 0.44 yuan.
Sunflower Pharmaceutical (002737.SZ): OTC and CHC products currently account for a high share of revenue
Gelonghui, March 27丨An investor asked Sunflower Pharmaceutical (002737.SZ) on the investor interactive platform, “How much does the sum of the revenue of your physical pharmacy and internet pharmacy account for the total revenue?” The company replied that currently OTC and CHC products account for a high proportion of the company's revenue. For details, please check the company's annual report data.
Sunflower Pharmaceutical (002737): New OTC management of an undervalued high-dividend brand leads the company to another success
Core logic: The company is an OTC target for high-quality brands with undervalued and high dividends. The PE-TTM valuation on 2024/3/11 was about 13 times, and the company's dividend ratio was over 50% in 2021-2022. The company relies on
Express News | Cinda Securities gave Sunflower Pharmaceuticals an initial rating for increasing its holdings.
Chinese Drug Regulator Accepts Application of Sunflower Pharma's Unit for Fexofenadine Hydrochloride Oral Suspension
China's National Medical Products Administration accepted the application of Sunflower Pharmaceutical Group's (SHE:002737) unit, Harbin Sunflower Pharmaceutical, to market its drug, fexofenadine hydro
Sunflower Pharmaceutical (002737.SZ): Fexofenadine hydrochloride oral suspension was approved for marketing
Gelonghui, Feb. 18: Sunflower Pharmaceutical (002737.SZ) announced that Harbin Sunflower Pharmaceutical Co., Ltd. (“Sunflower”), a wholly-owned subsidiary of the company, recently received a “Notice of Acceptance” issued by the State Drug Administration regarding the application for registration and marketing of fexofenadine hydrochloride oral suspension.
Wu Han of Zhongkang Technology: The key to solving the development problems of the traditional Chinese medicine industry is to break the “island effect”
The first Traditional Chinese Medicine Ecological Conference is expected to bring new opportunities and perspectives to enterprise development and industrial upgrading.
Company Q&A 丨 Sunflower Pharmaceutical: The company's adult and children's products include major health products
Gelonghui, November 24 | Investors asked Sunflower Pharmaceutical on an interactive platform: Does our company have a big health industry, and are our long-term growth goals clear? Sunflower Pharmaceutical's response: The company's adult and children's products include big health products. In the future, it will also gradually expand the fields of application of big health products to promote the improvement of the company's business performance.
Sunflower Pharmaceutical (002737.SZ): The company currently sells some agent varieties
Gelonghui November 3 | Sunflower Pharmaceutical (002737.SZ) stated on the investor interactive platform that from the perspective of improving the company's product structure, the company currently has some agent sales agents. The company will select varieties that are in line with the company's strategic layout and high product quality for cooperation, and continue to pay attention to product quality control risks during the cooperation.
[BT Financial Report Instantaneous Analysis] Sunflower Pharmaceutical's 2023 Three-Quarter Report: Significant performance growth, significant year-on-year increase in net profit
This earnings announcement time: 2023-10-25 16:16:34 Sunflower Pharmaceutical (stock code: 002737) is a leading company in the pharmaceutical industry. The company was founded in 2005 and is headquartered in China. As a comprehensive pharmaceutical company, Sunflower Pharmaceutical is committed to R&D, production and sales of innovative pharmaceuticals and medical devices. The company has a broad product line in various fields, including prescription drugs, non-prescription drugs, health products, and medical devices. The company's products cover many treatment fields, such as cardiovascular, digestive, nervous, respiratory, etc. Judging from the financial data,
No Data